- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO Picks Top Advances in Cancer Treatment
Advances in screening and prevention, treatments for refractory cancers, and ways to reduce cancer recurrence were part and parcel of the progress made against the disease in 2011, according to the American Society of Clinical Oncology.
A reduction in lung cancer death rates of 20% for high-risk individuals following low-dose computed tomography scanning was one of the more important screening advances of the past year. This was the first successful trial over many decades of trying to find a screening regimen for these patients, reported Steven I. Benowitz, MA, from ASCO, and colleagues.
Among the advances in new drug approvals was the clearance of crizotinib (Xalkori) for use in lung cancer patients whose tumor has a specific alteration in the anaplastic lymphoma kinase gene, the authors noted online in the Journal of Clinical Oncology. The 31% improved survival over two years was heralded as another example of successfully personalizing the treatment of cancers.
Source: Medpage Today
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
